Los Angeles, CA -- (SBWire) -- 07/26/2019 --The global Lewy body dementia treatment market is expected to see considerable growth in future, taking into account the high prevalence of dementia and mental disorders. Healthcare professionals and scientists involved in the treatment of Lewy body dementia and related research activities are sharing their findings and expertise to effectively combat the disease. Players are prophesied to enter into tactical merger and acquisition deals with investment groups and regional companies to maintain their market growth. Increase in collaborative research practices observed in the pharmaceutical industry is foretold to create opportunities in the global market.

In June 2019, the 2019 International Lewy Body Dementia Conference joined by global and Lewy Body Dementia Association researchers featured American artist Susan Schneider Williams, who was previously married to Robin Williams. Speakers at the conference shared new tactics to deal with Lewy body dementia and discussed about a consortia that researchers from South America, North America, Asia, and Europe are building to pool resources for Lewy body dementia treatment, clinical trials, biomarker discovery, and longitudinal observational studies.

Players to Diversify Product Portfolios through Partnerships with Healthcare Institutions

According to researchers, BioArctic AB, Sanofi AG, Eisai Co., Ltd., Mylan NV, Sumitomo Dainippon Pharma Co., Ltd., Bayer AG, Jazz Pharmaceuticals, Inc., Pfizer Inc., Immungenetics AG, Novartis AG, Eli Lilly and Company, and Noven Pharmaceuticals, Inc. are key players of the global Lewy body dementia treatment market. Companies are foreseen to sign partnership agreements with clinics and primary care hospitals to help expand their business and diversify their drug and treatment portfolios.

Get PDF template of this report: https://www.qyrconsulting.com/request-sample/7327

Key Takeaways

? Difficulty in diagnosing Lewy body dementia and high incidence of the disease to raise strong demand for new treatments

? Manufacturers to enter into partnerships with hospitals and clinics

? Cholinesterase inhibitors to secure a remarkable share of the global Lewy body dementia treatment market

? North America to gain significant market share with high diagnosis of Lewy body dementia in the region

By Drug Type

? Modafinil

? Cholinesterase Inhibitors

? Benzodiazepine

? Antipsychotic Drugs

? Antidepressants

? Carbidopa-Levodopa

By Indication

? Dementia with Lewy Bodies

? Parkinson's Disease

Among drug types, cholinesterase inhibitors are expected to gain a telling share of the global Lewy body dementia treatment market due to its fewer side effects. It could be trailed by antipsychotic drugs in terms of market share during the forecast period. The report also covers a couple of indication segments, viz. Parkinson's disease and dementia with Lewy bodies.

By Region

Regionally, North America is forecast to take the lead in the global Lewy body dementia treatment market because of important growth driving factors such as availability of high-quality healthcare facilities, favorable reimbursement conditions for patients requiring expensive drugs, and implementation of relevant dementia drug regulations. With India and China having a large geriatric population, Asia Pacific is foretold to show faster growth in the global market. Improving accessibility to dementia treatments could also work in the favor of the Asia Pacific market.

Get Complete Report within 24 hours: https://www.qyrconsulting.com/checkout/7327

About QYR Consulting
We established as a research firm in 2007 and have since grown into a trusted brand amongst many industries. Over the years, we have consistently worked toward delivering high-quality customized solutions for wide range of clients ranging from ICT to healthcare industries. With over 50,000 satisfied clients, spread over 80 countries, we have sincerely strived to deliver the best analytics through exhaustive research methodologies.